Replies to post #146489 on Biotech Values

[DewDiligence]

I heard the call. Copaxone continues to grow—in volume as well as $ sales—in spite of the existing and expected competition.

My $2.6B estimate for 2012 US Copaxone sales in #msg-75932085 may turn out to be too low.

[DewDiligence]

3Q12 US Copaxone sales were $775M, +3% YOY and +11% QoQ:

http://finance.yahoo.com/news/teva-reports-third-quarter-2012-110000915.html

US Copaxone sales for the first 9 months of 2012 were $2.09B, ahead of the pace to meet my estimate of $2.6B for the full year (#msg-75932085).